COX-2 and Colorectal Cancer
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2229-2251
Author(s):
A. Ferrandez, S. Prescott and R. W. Burt
COX-2 Inhibition in Esophagitis, Barretts Esophagus and Esophageal Cancer
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2267-2280
Author(s):
E. Piazuelo, P. Jimenez and A. Lanas
Cyclooxygenase-2 Inhibition and Gastric Cancer
Journal:
Current Pharmaceutical Design
Volume:
9
Page:
2281-2288
Author(s):
Xiao Hua Jiang and C. Y. Wong
Preface [Hot topic:Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman)]
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
i-i
Author(s):
Paul Workman
Overview: Translating Hsp90 Biology into Hsp90 Drugs
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
297-300
Author(s):
Paul Workman
Structure and Functional Relationships of Hsp90
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
301-323
Author(s):
Chrisostomos Prodromou and Laurence H. Pearl
Natural Product Origins of Hsp90 Inhibitors
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
325-330
Author(s):
Yoshimasa Uehara
Genes and Proteins Governing the Cellular Sensitivity to HSP90 Inhibitors: A Mechanistic Perspective
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
331-341
Author(s):
Alison Maloney, Paul A. Clarke and Paul Workman
The C-Terminal Half of Heat Shock Protein 90 Represents a Second Site for Pharmacologic Intervention in Chaperone Function
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
343-347
Author(s):
Monica G. Marcu and Leonard M. Neckers
The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Journal:
Current Cancer Drug Targets
Volume:
3
Page:
349-358
Author(s):
Luke Whitesell, Rochelle Bagatell and Ryan Falsey